BioSpace News Archive

GeNeuro is developing therapeutics that tackle the viral proteins that potentially contribute to neurodegeneration seen in patients with MS, amyotrophic lateral sclerosis (ALS) and even COVID-19.

Flagship Pioneering announced the launch of Sonata Therapeutics. The fledgling company was created by combining two Flagship companies, Inzen Therapeutics and Cygnal Therapeutics.

Following reports that Pfizer has declined study requests for Paxlovid, the company and NIH are said to be in conversation about potential studies assessing a longer treatment period of the antiviral.

Hengrui Pharma is seeking to make medicines more available and affordable worldwide with the launch of Luzsana that opens up access to treatment for hundreds of illnesses.

The current president, CEO and board member, Keith Kendall, is departing Aquestive. He will be replaced by Daniel Barber, its current chief operating officer.

Applied Molecular Transport (AMT) provided a strategy update on Wednesday. Part of the update includes reducing its workforce by about 40% and funneling resources into its lead program.

Virongy is expanding again and has committed to a $471,000 expansion with up to 70 new jobs.

Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.

Orgenesis is developing a point-of-care manufacturing platform for cell and gene and other advanced therapies to make them more widely available and significantly more affordable.

Bavarian Nordic A/S announced that the U.S. Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised the first options under the contract to supply a freeze-dried version of JYNNEOS® smallpox vaccine, thus allowing for the first doses of this version to be manufactured and invoiced in 2023 and 2024.